FY2024 EPS Estimates for Centessa Pharmaceuticals plc Increased by Analyst (NASDAQ:CNTA)

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for Centessa Pharmaceuticals in a note issued to investors on Tuesday, August 13th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of ($1.65) per share for the year, up from their prior forecast of ($1.68). The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.62) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ Q4 2024 earnings at ($0.45) EPS, FY2026 earnings at ($1.39) EPS, FY2027 earnings at ($0.59) EPS and FY2028 earnings at ($0.05) EPS.

A number of other equities analysts have also recently issued reports on CNTA. Morgan Stanley increased their target price on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Friday, June 21st. Oppenheimer reiterated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA traded down $0.41 during trading on Friday, hitting $12.68. 12,033 shares of the company were exchanged, compared to its average volume of 308,233. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 1-year low of $5.15 and a 1-year high of $13.56. The company has a market capitalization of $1.27 billion, a P/E ratio of -9.22 and a beta of 1.40. The business’s 50 day moving average is $9.80 and its 200-day moving average is $9.88.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02).

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CNTA. China Universal Asset Management Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 69.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock valued at $122,000 after acquiring an additional 4,423 shares during the last quarter. Quarry LP bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at $48,000. EntryPoint Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter worth $109,000. Sandia Investment Management LP bought a new position in Centessa Pharmaceuticals during the second quarter worth $90,000. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals in the second quarter valued at $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.